Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.38 USD | +0.09% |
|
-5.40% | +66.86% |
01/07 | Y-mAbs Therapeutics Appoints Peter Pfreundschuh as CFO | MT |
01/07 | Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+66.86% | 50Cr | |
+15.58% | 12TCr | |
+16.60% | 11TCr | |
+17.55% | 2.59TCr | |
-24.33% | 1.93TCr | |
-19.14% | 1.6TCr | |
-17.95% | 1.57TCr | |
-46.81% | 1.49TCr | |
+58.78% | 1.45TCr | |
+4.91% | 1.39TCr |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- Morgan Stanley Adjusts Price Target on Y-mAbs Therapeutics to $7 From $4, Maintains Underweight Rating